Business, energy, technology, markets and global industry news from Business News Today

Gilead Sciences

PharmaDeviceNews Gilead Sciences
Representative image of an HIV prevention consultation, as Gilead Sciences’ once weekly oral Yeztugo filing puts long acting PrEP and future FDA review in focus.
Pharma & Biotech

Gilead’s once weekly Yeztugo bid could challenge the old daily pill versus injection divide

Read how Gilead’s once weekly oral Yeztugo filing could reshape HIV prevention, PrEP adherence and long acting therapy competition.

Read More
Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.
Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.

Read More
Pharma & Biotech

Why Gilead Sciences’ Livdelzi data could reshape treatment goals in primary biliary cholangitis

Find out how Gilead Sciences’ Livdelzi trial data could reshape PBC treatment goals and strengthen the case for ALP normalization.

Read More
Representative image: Healthcare workers review treatment supplies in a regional clinic as Gilead Sciences and the World Health Organization renew efforts to expand AmBisome access and strengthen visceral leishmaniasis elimination programmes.
Pharma & Biotech

Why Gilead’s visceral leishmaniasis collaboration with WHO matters beyond drug donation

Gilead’s WHO pact targets kala-azar access, but diagnostics, treatment delivery and East Africa execution will decide the impact.

Read More
Representative image: Scientists review antibody-drug conjugate research in an oncology laboratory as Gilead Sciences’ Tubulis acquisition sharpens focus on next-generation ADC platforms, solid tumour pipelines and cancer drug development strategy.
Pharma & Biotech

Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy

Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.

Read More
Representative image: An oncology specialist reviews treatment information with a breast cancer patient in a clinical setting, reflecting Gilead Sciences’ Trodelvy regulatory progress in first-line metastatic triple-negative breast cancer care.
Pharma & Biotech

Gilead’s Trodelvy gains EU regulatory momentum, but the first-line TNBC fight is only beginning

Gilead’s Trodelvy may move earlier in metastatic TNBC. The EU signal could reshape first-line ADC use, but adoption questions remain.

Read More
Pharma & Biotech

How Gilead Sciences, Inc. could strengthen its liver disease franchise through Hepcludex commercialization

FDA approval of Hepcludex gives HDV its first U.S. therapy. Find out how this could reshape liver disease treatment and Gilead’s strategy.

Read More
Representative image: Gilead Sciences’ HIV drug growth helped lift its Q1 performance, highlighting how Biktarvy, Descovy and long-acting prevention therapies remain central to the company’s biopharma growth story.
Pharma & Biotech

Gilead’s Q1 shows HIV momentum remains powerful, but diversification is still unfinished

Gilead’s HIV engine is roaring again. But acquisition costs and oncology pressure leave investors asking how durable the reset really is.

Read More
Pharma & Biotech

Why Gilead’s Arcellx acquisition approval could reshape the multiple myeloma CAR-T race

Gilead has cleared regulatory hurdles for Arcellx. Read why the anito-cel takeover could reshape the multiple myeloma CAR-T market.

Read More
Pharma & Biotech

Why Tubulis gives Gilead more than just another antibody-drug conjugate asset

Gilead is acquiring Tubulis to expand its antibody-drug conjugate pipeline. Read what the deal changes for oncology strategy and ADC competition.

Read More